PHI with Hereditary angioedema
How does this condition affect your private health insurance?
Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling (edema) in various body parts, including the skin, gastrointestinal tract, and upper airways. These attacks are painful, disfiguring, and potentially life-threatening if they affect the larynx, leading to suffocation. It is caused by a deficiency or dysfunction of the C1 esterase inhibitor (C1-INH) protein. Triggers can include stress, trauma, or medical procedures, but often no trigger is identified. Early diagnosis and appropriate management are essential to prevent severe complications and improve patient quality of life.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 30%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Typically 2 to 5 days per attack if untreated.
Duration of Illness (Lifetime)
Lifelong, as it is a chronic genetic condition.
Cost of Treatment (Initial)
High, ranging from several thousands to tens of thousands of dollars for acute treatment per episode.
Cost of Treatment (Lifetime)
Very high, potentially hundreds of thousands to millions of dollars due to chronic nature and expensive prophylactic and acute medications.
Mortality Rate
Low with appropriate and timely treatment, but significantly higher (up to 25-30%) in cases of untreated laryngeal edema.
Risk of Secondary Damages
High, including chronic pain, anxiety, depression, reduced quality of life, and potential for unnecessary surgeries due to misdiagnosed abdominal attacks.
Probability of Full Recovery
Virtually zero; HAE is a lifelong genetic condition. Treatment focuses on managing symptoms and preventing attacks.
Underlying Disease Risk
Low, as HAE is a primary genetic disorder. However, patients may experience comorbidities common in the general population.